Accent Therapeutics Stock

www.accenttx.comHealthcare / BioTech & PharmaFounded: 2017

Accent Therapeutics is a biopharmaceutical company working to design efficient cancer treatments by looking at small molecule precision therapies. Looking beyond traditional therapies that focus on mutation-specific vulnerabilities, the team is striving to find and target intracellular dependencies for multiple types of cancer using RNA-modifying protein (RMP) biology. Accent Therapeutics was founded in 2017 by Robert A. Copeland, Ph. D., and headquartered in Lexington, MA.

Register To Buy and Sell Shares

For more details on financing and valuation for Accent Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Accent Therapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Accent Therapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

Robert Copeland Ph.D
Co-Founder, President & Chief Scientific Officer
Howard Chang Ph.D
Co-Founder & Scientific Advisor
Shakti Narayan Ph.D
Chief Executive Officer
Nicole Heifner
Chief Financial Officer
David Brower
Chief Business Officer
Jason Sager MD
Chief Medical Officer

Board Members

Caroline Stout
EcoR1 Capital
Charles Kunsch Ph.D
AbbVie Ventures
Jason Rhodes
Atlas Venture
Naveen Krishnan MD
Mirae Asset Capital Life Science
Sean Evans Ph.D
Johnson & Johnson Innovation

Frequently Asked Questions About Accent Therapeutics’ Stock

plusminus
Can you buy Accent Therapeutics’ stock?
Accent Therapeutics is not publicly traded on NYSE or NASDAQ in the U.S. To buy Accent Therapeutics’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Accent Therapeutics’ stock?
Yes, you can sell stock of a private company like Accent Therapeutics. Forge can help you sell your Accent Therapeutics stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Accent Therapeutics’ stock price?
Accent Therapeutics is a privately held company and therefore does not have a public stock price. However, you may access Accent Therapeutics’ private market stock price with Forge Data.
plusminus
What is Accent Therapeutics’ stock ticker symbol?
Accent Therapeutics does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Two more pharmas practice their Accent, invest in $75M series C round
Accent Therapeutics has reeled in investments from two more pharmaceutical companies as part of a $75M series C, the latest validation for the RNA drug developer. Bristol Myers Squibb and Johnson & Johnson’s investment arm, JJDC, participated in the funding round that was announced Tuesday, which was led by the recently launched Mirae Asset Capital Life Science. The two pharmas join AbbVie’s venture arm which had previously participated in the biotech's series B.
Updated on: May 17, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.